|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system
Arnold Man Nok Chui 1 , Thomas Chung Cheung Yau 2 , Tan To Cheung 1 3
Affiliations
Affiliations
1
Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
2
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
3
Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
PMID: 33330826 PMCID: PMC7731182 DOI: 10.35772/ghm.2020.01062
Abstract
In Hong Kong, liver cancer is the fifth most common cancer and the third most common cause of cancer deaths. The prevalence of hepatitis B is high in Hong Kong because of the high rate of hepatitis B virus infection, and chronic hepatitis B has remained the leading cause of hepatocellular carcinoma in the city, accounting for 80% of all cases in the period from 1992 to 2016. In view of the different etiologies of hepatocellular carcinoma around the world, a group of liver experts in Hong Kong developed the Hong Kong Liver Cancer staging system in order to provide more aggressive treatment guidance (predominantly a wider use of surgical resection) for Asian patients of hepatocellular carcinoma. In this article focussing on the Hong Kong Liver Cancer staging system, we briefly reviewed the screening criteria adopted in Hong Kong for liver resection, local ablation, transcatheter arterial chemoembolization, transcatheter arterial radioembolization, stereotactic body radiation therapy, and systemic therapy.
Keywords: HCC; HKLC; SBRT; ablation; cirrhosis; hepatectomy; laparoscopic; liver cancer staging; systemic therapy.
2020, National Center for Global Health and Medicine. |
|
发表于 2020-12-18 17:51